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We read with interest the paper published by Repressé and colleagues \[[@B1]\]. Coagulation management is a challenge during extracorporeal membrane oxygenation (ECMO) due to complex hemostatic and inflammatory responses associated with the underlying conditions that include infection, sepsis, surgery, and/or traumatic injury \[[@B2]\]. Repressé and colleagues present the first algorithm-based approach to bleeding in ECMO patients. However, additional perspectives are important to consider.

First, activated partial thromboplastin time or antiactivated factor × monitoring are routinely used to monitor heparin therapy in ECMO patients, despite intraindividual and inter-individual variability \[[@B3]\]. Rotational thromboelastometry (ROTEM^®^; TEM^®^International GmbH, Munich, Germany) is also increasingly used in the ICU to rapidly assess the coagulation status, including clotting factors, fibrinogen levels, and whole blood clotting \[[@B4]\]. Moreover, this test also facilitates fibrinolytic pathway evaluation, which cannot be easily explored by routine laboratory tests. We believe ROTEM^®^could be used to design an algorithm-based approach to bleeding in ECMO patients and follow fibrinogen consumption associated with hyperfibrinolysis, an important cause of bleeding. For this reason, anti-fibrinolytic agents should be considered in the multimodal approach (Figure [1](#F1){ref-type="fig"}), an important point the authors omitted in their algorithm.

![**Hyperfibrinolysis diagnosed in a bleeding extracorporeal membrane oxygenation patient**. **(a)**Baseline EXTEM, **(b)**baseline FIBTEM, **(c)**EXTEM and **(d)**FIBTEM thromboelastometry tests after the administration of tranexamic acid (TXA; 10 mg/kg) and fibrinogen concentrates (2 g).](cc12682-1){#F1}

Second, adverse events including 32% venous thrombosis and a 2.5% incidence of fatal pulmonary embolism have already been reported in ECMO patients \[[@B5]\]. In another series, Combes and colleagues reported a 10% incidence of femoral vein and 7% incidence vena cava thrombosis \[[@B6]\]. Recombinant activated factor VII is associated with thromboembolic events \[[@B7]\] and should be used with caution until additional data help us evaluate the benefit-to-risk administration in bleeding ECMO patients.
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